Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine
20 janv. 2021 08h00 HE
|
Gritstone Oncology, Inc
— Deal provides nonexclusive access to Genevant’s leading LNP technology for use in Gritstone’s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate...
Gritstone Advances Second Generation COVID-19 Vaccine “CORAL” Program with Support from NIAID; Program has Potential to Protect Against Mutant Variants of SARS-CoV-2
19 janv. 2021 06h00 HE
|
Gritstone Oncology, Inc
--Gritstone to Host Conference Call Today at 8:00 a.m. ET-- EMERYVILLE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company...
Gritstone Oncology to Present at the 39th Annual J.P. Morgan Healthcare Conference
11 janv. 2021 08h00 HE
|
Gritstone Oncology, Inc
EMERYVILLE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...
Gritstone Oncology Announces Private Placement Financings Totaling $125 Million
28 déc. 2020 08h00 HE
|
Gritstone Oncology, Inc
--Received Gross Proceeds of $110 Million from Previously Announced PIPE Financing----Executed Additional PIPE Financing of $15 Million-- EMERYVILLE, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) --...
Gritstone Oncology Announces $110 Million Private Placement
23 déc. 2020 08h33 HE
|
Gritstone Oncology, Inc
EMERYVILLE, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...
Gritstone Oncology Reports Third Quarter Financial Results and Recent Highlights
05 nov. 2020 09h01 HE
|
Gritstone Oncology, Inc
EMERYVILLE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...
Gritstone Oncology Advances into Phase 2 Expansion Cohorts for its Personalized Neoantigen Immunotherapy GRANITE and its Off-the-Shelf Neoantigen Immunotherapy SLATE
02 nov. 2020 08h00 HE
|
Gritstone Oncology, Inc
--The Phase 1 portions of the studies are closed for enrollment; patient treatment and follow-up for efficacy and safety continues-- EMERYVILLE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Gritstone...
Gritstone Oncology Announces Updated Presentation Time at Cantor Virtual Global Healthcare Conference
15 sept. 2020 08h00 HE
|
Gritstone Oncology, Inc
EMERYVILLE, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...
Gritstone Oncology to Webcast Presentations from Two Upcoming Investor Conferences in September
08 sept. 2020 08h00 HE
|
Gritstone Oncology, Inc
EMERYVILLE, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies...
Gritstone Oncology Reports Second Quarter Financial Results and Recent Highlights
05 août 2020 09h01 HE
|
Gritstone Oncology, Inc
EMERYVILLE, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to...